Treatment of Uterine Sarcoma in High-Grade Endometrial Stromal Sarcoma or Undifferentiated Uterine Sarcoma
High-grade endometrial stromal sarcoma (HG-ESS) and undifferentiated uterine sarcoma (UUS) are rare, aggressive subtypes of uterine sarcoma. Together they represent a small but clinically distinct fraction of cases, each requiring a specific systemic treatment approach.
Clinical scenario
This protocol addresses patients with high-grade endometrial stromal sarcoma or undifferentiated uterine sarcoma — subtypes that collectively account for approximately 5% of uterine sarcomas — in whom systemic therapy is indicated.
Treatment approach (partial overview)
Systemic therapy for this scenario draws on several distinct options, including both combination regimens and single-agent approaches. Agent selection is guided by prior treatment history.
The complete agent choices, sequencing criteria, and evidence ratings are available in the full protocol.
References
- HG-ESS and UUS collectively represent about 5% of uterine sarcomas.
- Systemic therapy options include continuous infusion of high-dose ifosfamide; or gemcitabine and docetaxel; pazopanib or trabectedin as single agent. The choice depends on the agent used in first-line setting (IV, B).
DOI: 10.1136/ijgc-2024-005823
View source ↗